Tweet
J Am Heart Assoc
. 2020 Jul 15;e016812.
doi: 10.1161/JAHA.120.016812. Online ahead of print.
The prevalence of cardiovascular comorbidities in COVID-19, SARS and MERS: pooled analysis of published data
Yang Liu 1 , Shaohui Wu 1 , Mu Qin 1 , Weifeng Jiang 1 , Xu Liu 1
Affiliations
- PMID: 32673529
- DOI: 10.1161/JAHA.120.016812
Abstract
Background COVID-19 is spreading widely around the world. We conducted this meta-analysis to explore the prevalence of cardiovascular comorbidities in COVID-19, SARS and MERS cases.Relevant reports updated to April 17 2020 were searcher from PubMed, Embase, Web of Science and the Cochrane Library with no restriction on language. A random-effects model was used in this meta-analysis to obtain pooled proportions of cardiovascular comorbidities in COVID-19, SARS and MERS. A total of 22 studies (12 for COVID-19, 4 for SARS and 6 for MERS) were included in this analysis, and the average age of COVID-19, SARS and MERS was 46.41 ? 1.79 years, 39.16 ? 2.25 years and 52.51 ? 4.64 years, respectively. Proportions of cardiovascular comorbidities in coronavirus diseases were as follows: COVID-19: proportion of hypertension was 17.1% (95% CI 13.2-20.9%), proportion of cardiac disease was 4.5% (95% CI 3.6-5.5%) and proportion of diabetes mellitus was 8.5% (95% CI 5.5-11.4%); SARS: proportion of hypertension was 4.5% (95% CI 2.0-7.0%), proportion of cardiac disease was 2.1% (95% CI 0.6-3.7%) and proportion of diabetes mellitus was 3.7% (95% CI 1.0-6.4%); MERS: proportion of hypertension was 30.3% (95% CI 18.3-42.2%), proportion of cardiac disease was 20.9% (95% CI 10.7-31.1%) and proportion of diabetes mellitus was 45.4% (95% CI 27.3-63.5%). Conclusions The prevalence of cardiovascular comorbidities varies among different coronavirus-associated diseases. With the development of time, proportions of cardiovascular comorbidities in COVID-19 need further attention.
Keywords: COVID‐19; MERS; SARS; cardiovascular comorbidities; pooled analysis; prevalence.